Diyabetik Nefropati'ye Genel Bir Bakış

AKBABA, GÜLHAN; AKBABA, Eren

Diyabetik Nefropati'ye Genel Bir Bakış

Eren AKBABA, (Muğla Sıtkı Koçman Üniversitesi, Muğla, Türkiye)

Gülhan AKBABA (Muğla Sıtkı Koçman Üniversitesi, Muğla, Türkiye)

Haseki Tıp Bülteni

3 2

Yıl: 2015 Cilt: 53 Sayı: 1 Sayfa Aralığı: 10 - 15 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Diyabetik Nefropati'ye Genel Bir Bakış

Öz:

Diyabetik nefropati önemli bir morbidite ve mortalite nedeni olmanın ötesinde kardiyovasküler nedenlerle ölüm sıklığında ciddi bir artışı da beraberinde getirmektedir. Öncelikli amaç diyabetin tedavisi ve risk faktörlerinin kontrol altında tutulmasıdır. Diyabetik nefropatide ortaya çıkan yapısal değişiklikler tüm renal kompartmanları etkileyebilmektedir. Renal ateroskleroz ve arteriyoloskleroz diyabetiklerdeki sistemik damar lezyonlarının önemli bölümünü oluşturmaktadır. Diyabetik hastalarda iyi glisemik ve sıkı kan basıncı kontrolü ile mikrovasküler komplikasyonların önlenmesi açısından önemlidir. Sunduğumuz derlemede, giderek artan oranda bir sağlık sorunu olan diyabetik nefropati hakkında genel bilgi vermek ve bu duruma dikkati çekmek amaçlanmıştır. (Haseki T p Bülteni 2015; 53: 16-9)

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Diyabetik Nefropati ye Genel Bir BaAn Overview of Diabetic Nephropathy

Öz:

Diabetic nephropathy is a significant cause of morbidity and mortality associated with a high risk of cardiovascular complications. The primary goal should be treatment and control of risk factors. Structural changes due to diabetic nephropathy may affect all the renal compartments. Atherosclerotic renal artery stenosis and arteriolosclerosis constitute an important part of systemic vascular lesions in diabetics. Close monitoring of blood pressure and glycemic control is important in the prevention of microvascular complications. In this review, we aimed to give an outline of diabetic nephropathy which is an increasing public health problem and to draw attention to this condition. (The Medical Bulletin of Haseki 2015; 53: 16-9)

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency.Lancet 2010;376:911-21.
2. Lawrence M. Nelson. Primary Ovarian Insufficiency. N Engl JMed 2009;360:606-14.
3. van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 1997;68:95-102.
4. Gezer A, Şenturk LM, Ertungealp E. Menopoz ve postmenopoz. In: Cicek MN, Akyurek C, Celik C, Haberal A, Kadın Hastalıkları ve Doğum Bilgisi. Ankara, Guneş Kitabevi; 2004. p. 1163-82.
5. Rebar RW, Erickson GF, Yen SS. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil Steril 1982;37:35-41.
6. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2003;18:199-206.
7. O’Herlihy C, Pepperell RJ, Evans JH . The significance of FSH elevation in young women with disorders of ovulation . BR Med J 1980;281:1447-50.
8. Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfá E. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014;13:427-30.
9. Jin M, Yu Y, Huang H. An update on primary ovarianinsufficiency. Sci China Life Sci 2012;55:677-86.
10. Nelson LM, Anasti JN, Flack MR. Premature ovarian failure. In: Adashi EY, Rock JA, Rosenwaks Z, eds. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott–Raven; 1996. p. 1393-410.
11. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53:804-10.
12. Zinn AR, Tonk VS, Chen Z, et. al. Evidence for a turner syndrome locus or loci at Xp113-p221. Am J Hum Genet 1999;63:1757-66.
13. Simpson JL. and Rajkovic A. Ovarian differentiation and gonadal failure. Am J Med Genet 1999;89:186-200.
14. Pasquino AM, Passeri F, Pucarelli I, Segni M, Municchi G. Spontaneous pubertal development in Turner’s syndrome. Italian Study Group for Turner’s Syndrome. J Clin Endocrinol Metab 1997;82:1810-3.
15. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update 2005;11:391-410.
16. Skuse DH, James RS, Bishop DV, et al. Evidence from Turner’s syndrome of an imprinted X-linked locus affecting cognitive function. Nature 1997;387:705-8.
17. Garber K, Smith KT, Reines D, Warren ST. Transcription, translation and fragile X syndrome. Curr Opin Genet Dev 2006;16:270-5.
18. Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003;72:454-64.
19. Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril 2007;87:456-65.
20. Conway G, Payne N, Webb J, Murray A, Jacobs P. Fragile X premutation screening in women with premature ovarian failure. Hum Reprod 1998;13:1184-7.
21. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study preliminary data. Am J Med Genet 1999;83:322-5.
22. Aittomäki K, Lucena JL, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditery hipergonadotrophic ovarian failure. Cell 1995;82:959-68.
23. Aittomäki K, Herva R, Stenman UH, et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 1996;81:3722-6.
24. Juengel JL, McNatty KP. The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicular development. Hum Reprod Update 2005;11:143-60.
25. Wilcox LS, Mosher WD. Use of infertility services in the United States. Obstet Gynecol 1993;82:122-7.
26. Shelling AN, Burton KA, Chand AL, et al. İnhibin: a candidate gene for premature ovarian failure. Hum Reprod 2000;15:2644-9.
27. Crisponi L, Deiana M, Loi A, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ ptosis/epicanthus inversus syndrome. Nat Genet 2001;27:159-66.
28. Cocquet J, Pailhoux E, Jaubert F, et al. Evolution and expression of FOXL2. J Med Genet 2002;39:916-21.
29. Berry G. Galactosemia and amenorrhea in the adolescent. Ann N Y Acad Sci 2008;1135:112-7.
30. Smith JA, Vitale S, Reed GF, et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol 2004;122:151-6.
31. Cervera R, Balasch J. Bidirectional eff ects on autoimmunity and reproduction. Hum Reprod Update 2008;14:359-66.
32. Lebovic DI, Naz R. Premature ovarian failure: Think “autoimmune disorder”. Sexuality, Reproduction and Menopause 2004;2:230-3.
33. Novosad J, Kalantaridou S, Tong Z, Nelson L. Ovarian antibodies as detected by indirect immunofl uorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 2003;3:2.
34. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in fi ve-year survivors of childhood and adolescent cancer: The childhood cancer survivor study. J Clin Oncol 2001;19:3163-72.
35. Chapman R. Eff ect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982;9:84-94.
36. Bines J, Oleske D, Cobleigh M. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
37. Sonmezer M, Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10:251-66.
38. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002;187:93-105.
39. Shamberger R, Rosenberg S, Seipp C, Sherins R. Eff ects of highdose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 1981;65:739-46.
40. Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin releasing hormone agonists for prevention of chemotherapyinduced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7.
41. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7.
42. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 2009;18:311-9.
43. Panay N, Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol 2009;23:129-40.
44. Rebar R, Erickson G, Yen S. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil Steril 1982;37:35-41.
45. Petraglia F, Zanin E, Faletti A. İnhibins: Paracrine and endocrine effects in female reproductive function. Curr Opin Obstet Gynecol 1999;11:241-7.
46. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet Journal of Rare Diseases 2006;1:9.
47. Nelson LM, Anasti JN, Kimzey LM, et al. Development of luteinized graafi an follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994;79:1470-5.
48. van Kasteren Y, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999;5:483-92.
49. Tarani L, Lampariello S, Raguso G, et al. Pregnancy in patients with Turner’s syndrome: six new cases and review of literature. Gynecol Endocrinol 1998;12:83-7.
50. Hovatta O. Pregnancies in women with Turner’s syndrome. Ann Med 1999;31:106-10.
51. Betterle C, Volpato M, Rees Smith B, et al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. J Clin Endocrinol Metab 1997;82:932-8.
52. Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev 1997;18:107-34.
53. Kok HS, Kuh D, Cooper R, et al. Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause 2006;13:19-27.
54. Farrag A, Khedr E, Abdel-Aleem H, Rageh T. Eff ect of surgical menopause on cognitive functions. Dement Geriatr Cogn Disord 2002;13:193-8.
55. Nappi R, Sinforiani E, Mauri M, Bono G, Polatti F, Nappi G. Memory functioning at menopause: impact of age in ovariectomized women. Gynecol Obstet Invest 1999;47:29-36.
56. Snowdon DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health 1989;79,709-14.
57. Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulator disturbances. N Engl J Med 1990;323:1221-7.
58. Cann C, Genant H, Ettinger B, Gordan G. Spinal mineral loss in oopherectomized women. JAMA 1980;244:2056-9.
59. Cann C, Martin M, Genant H, Jaffe R. Decreased spinal mineral content in amenorrheic women. JAMA 1984;251:626-9.
60. Davies MC, Hall ML, Jacobs HS. Bone mineral loss in young women with amenorrhoea. BMJ 1990;301:790-3.
61. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008;68:499-509.
62. Mishell DR Jr, Nakamura RM, Crosignani PG, et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol 1971;111:60-5.
63. Scarabin PY, Alhenc-Gelas M, Plu- Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/ progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8.
64. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362: 428-32.
65. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5.
66. Gibbons WE, Moyer DL, Lobo RA, Roy S, Mishell DR Jr. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986;154:456-61.
67. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 1999;32:161-70.
68. Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2004;82:33-9.
69. Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10: 181-94.
70. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-10.
71. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005;353:318-21.
72. Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin’s disease. Oncologist 2007;12:1437-42.
73. Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008;23:2266-72.
74. Silber SJ, DeRosa M, Pineda J, et al. A series of monozygotic twins discordant for ovarian failure: ovary transplantation (cortical versus microvascular) and cryopreservation. Hum Reprod 2008;23:1531-7.

APA	AKBABA E, AKBABA G (2015). Diyabetik Nefropati'ye Genel Bir Bakış. , 10 - 15.
Chicago	AKBABA Eren,AKBABA GÜLHAN Diyabetik Nefropati'ye Genel Bir Bakış. (2015): 10 - 15.
MLA	AKBABA Eren,AKBABA GÜLHAN Diyabetik Nefropati'ye Genel Bir Bakış. , 2015, ss.10 - 15.
AMA	AKBABA E,AKBABA G Diyabetik Nefropati'ye Genel Bir Bakış. . 2015; 10 - 15.
Vancouver	AKBABA E,AKBABA G Diyabetik Nefropati'ye Genel Bir Bakış. . 2015; 10 - 15.
IEEE	AKBABA E,AKBABA G "Diyabetik Nefropati'ye Genel Bir Bakış." , ss.10 - 15, 2015.
ISNAD	AKBABA, Eren - AKBABA, GÜLHAN. "Diyabetik Nefropati'ye Genel Bir Bakış". (2015), 10-15.

APA	AKBABA E, AKBABA G (2015). Diyabetik Nefropati'ye Genel Bir Bakış. Haseki Tıp Bülteni, 53(1), 10 - 15.
Chicago	AKBABA Eren,AKBABA GÜLHAN Diyabetik Nefropati'ye Genel Bir Bakış. Haseki Tıp Bülteni 53, no.1 (2015): 10 - 15.
MLA	AKBABA Eren,AKBABA GÜLHAN Diyabetik Nefropati'ye Genel Bir Bakış. Haseki Tıp Bülteni, vol.53, no.1, 2015, ss.10 - 15.
AMA	AKBABA E,AKBABA G Diyabetik Nefropati'ye Genel Bir Bakış. Haseki Tıp Bülteni. 2015; 53(1): 10 - 15.
Vancouver	AKBABA E,AKBABA G Diyabetik Nefropati'ye Genel Bir Bakış. Haseki Tıp Bülteni. 2015; 53(1): 10 - 15.
IEEE	AKBABA E,AKBABA G "Diyabetik Nefropati'ye Genel Bir Bakış." Haseki Tıp Bülteni, 53, ss.10 - 15, 2015.
ISNAD	AKBABA, Eren - AKBABA, GÜLHAN. "Diyabetik Nefropati'ye Genel Bir Bakış". Haseki Tıp Bülteni 53/1 (2015), 10-15.